Download citation file:
From the Centers for Disease Control and Prevention, Emory University School of Medicine, and Emory Center for AIDS Research, Atlanta, Georgia; Medtronic, Memphis, Tennessee; University of Washington, Seattle, Washington; and University of Colorado School of Medicine, Denver, Colorado.
Acknowledgments: The authors thank Laura Doyle, Josephine Ehret, Connie Lenderman, James Thomas, and Karen Winterscheid for antimicrobial susceptibility testing and specimen handling. They acknowledge the substantial contributions of the sexually transmitted disease clinics and the local laboratories that participated in the Gonococcal Isolate Surveillance Project during 1988 to 2003. They also thank Maya Sternberg for providing additional statistical input and Gary W. Procop and Hillard S. Weinstock for project support.
Grant Support: The Gonococcal Isolate Surveillance Project is funded by the Centers for Disease Control and Prevention, U.S. Department of Health and Human Services.
Potential Financial Conflicts of Interest:Grants received: W.L.H. Whittington (Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases).
Requests for Single Reprints: Susan A. Wang, MD, MPH, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Mail Stop G-37, 1600 Clifton Road, Atlanta, GA 30333; e-mail, email@example.com.
Current Author Addresses: Dr. Wang: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Mail Stop G-37, 1600 Clifton Road, Atlanta, GA 30333.
Ms. Harvey and Dr. Zaidi: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Mail Stop E-63, 1600 Clifton Road, Atlanta, GA 30333.
Ms. Conner: Medtronic, 2600 Sofamor Danek Drive, A.3.040, Memphis, TN 38132.
Dr. Knapp: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Mail Stop A-12, 1600 Clifton Road, Atlanta, GA 30333.
Dr. Whittington: Department of Medicine, R/T Room 627 (Box 359742), Harborview Medical Center, 300 Ninth Avenue, Seattle, WA 98104.
Dr. del Rio: Department of Medicine, Grady Memorial Hospital, 69 Jesse Hill Jr. Drive, Atlanta, GA 30303.
Dr. Judson: Departments of Medicine and Preventive Medicine, University of Colorado Health Sciences Center, 2200 East 9th Avenue, Box B-119, Denver, CO 80262.
Dr. Holmes: Center for AIDS and STD, University of Washington, Box 359931, 325 Ninth Avenue, Seattle, WA 98104.
Author Contributions: Conception and design: S.A. Wang, J.S. Knapp, F.N. Judson.
Analysis and interpretation of the data: S.A. Wang, A.A. Zaidi, J.S. Knapp, W.L.H. Whittington, F.N. Judson, K.K. Holmes.
Drafting of the article: S.A. Wang, A.A. Zaidi, C. del Rio, K.K. Holmes.
Critical revision of the article for important intellectual content: S.A. Wang, A.A. Zaidi, J.S. Knapp, W.L.H. Whittington, C. del Rio, F.N. Judson, K.K. Holmes.
Final approval of the article: S.A. Wang, S.M. Conner, A.A. Zaidi, J.S. Knapp, W.L.H. Whittington, C. del Rio, F.N. Judson, K.K. Holmes.
Provision of study materials or patients: W.L.H. Whittington, C. del Rio, F.N. Judson.
Statistical expertise: S.A. Wang, A.A. Zaidi.
Obtaining of funding: S.A. Wang.
Administrative, technical, or logistic support: S.A. Wang, A.B. Harvey, S.M. Conner, F.N. Judson.
Collection and assembly of data: S.A. Wang, A.B. Harvey, S.M. Conner, W.L.H. Whittington, F.N. Judson.
From 1988 to 2003, GISP collected 82 064 isolates from men with urethral gonorrhea who attended sexually transmitted disease clinics in 37 cities (range, 21 to 30 cities per year). A median of 5088 isolates were collected each year (range, 4544 to 6552 isolates per year) (Table 1). Clinics in 16 cities participated for all 16 years and contributed 53 593 (65.3%) of the isolates. When we restricted analyses to these clinics, demographic or antimicrobial resistance trends were not affected.
*“Other” for 2003 (3.2%) includes no therapy (1.8%) and macrolide (0.6%), levofloxacin (0.4%), and other (0.4%) therapy. †“Other cephalosporins” for 2003 (4.6%) include cefpodoxime, 200 mg (4.0%); cefpodoxime, 400 mg (0.5%); and ceftizoxime (0.1%). ‡Marketing of cefixime tablets in the United States was discontinued in October 2002.
PPNG = penicillinase-producing N. gonorrhoeae (β-lactamase–positive; tetracycline MIC <16.0 µg/mL); TRNG = plasmid-mediated, tetracycline-resistant N. gonorrhoeae (β-lactamase–negative; tetracycline MIC ≥16.0 µg/mL); PPNG-TRNG = N. gonorrhoeae with plasmid-mediated resistance to both penicillin and tetracycline (β-lactamase–positive; tetracycline MIC ≥16.0 µg/mL); PenR = chromosomally mediated, penicillin-resistant N. gonorrhoeae (β-lactamase–negative; penicillin MIC ≥2.0 µg/mL; tetracycline MIC <2.0 µg/mL); TetR = chromosomally mediated, tetracycline-resistant N. gonorrhoeae (β-lactamase–negative; penicillin MIC <2.0 µg/mL; tetracycline MIC, 2.0 to 8.0 µg/mL); CMRNG = N. gonorrhoeae with chromosomally mediated resistance to penicillin and tetracycline (β-lactamase–negative; penicillin MIC ≥2.0 µg/mL; tetracycline MIC, 2.0 to 8.0 µg/mL); MIC = minimum inhibitory concentration.
Please read the other comments before posting. Contributors must reveal any conflict
Comments are moderated and will appear on the site at the discretion of The American
College of Physicians editorial staff. Please be sure your email address is
updated in your account, otherwise the American College of Physicians will not be
able to contact you about your comment.
Anyone can submit a comment any time after publication, but only those submitted within 4 weeks of an article’s publication will be considered for print publication. One month after publication, editors review all posted comments and select some for publication in the Letters section of the print version of Annals. (Not peer reviewed)
Authors: No more than 5
Text: Word Limit 400 (excludes references), 5 references, no figures or tables
* = Required Field
Disclosure of Any Conflicts of Interest*
(applies to the past 5 years and foreseeable future) Indicate any potential conflicts
of interest of each author below, including specific financial interests and relationships
and affiliations relevant to the subject matter or materials discussed in the manuscript
(eg, employment/affiliation, grants or funding, consultancies, honoraria, speakers
bureau, stock ownership or options, expert testimony, royalties, donation of medical
equipment, or patents filed, received, or pending). If all authors have none, check
"No potential conflicts or relevant financial interests" in the box below. Please
also indicate any funding received in support of this work. The information will
be posted with your response.
It is with great interest that I reviewed the article "Antimicrobial Resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: The Spread of Fluoroquinolone Resistance" by Wang et al which summarizes the growing issue of resistance in treating STD's. However, I was surprised to see the high incidence of gonorrhoeae in 74.1% of African American male patients. This may lead to a false racial bias about the incidence of GC in the United States. I question the validity of this number due to the lack of DNA testing of urine samples which is the preferred method in many private practices and clinics. This test is more expensive(cpt code 87591) with a cost of $69.00 for the N. gonorrhoeae test alone. The urine DNA testing is also routinely done for C. trachomatis at an additional cost of $69.00. Patients undergoing the DNA urine tests thus would need $138.00 plus the costs of the office visit and subsequent medicines which often are given empirically due to lack of followup. Thus, patients receiving such care would usually be insured and possibly of more varied ethnicity. Additional studies of all socioeconomic classes is warranted.
The article by Wang et al was highly interesting and provided conclusive evidence that Gonococcal resistance to fluoroquinolones is on the rise. (1) Given the ever increasing menace of sexually transmitted infections, especially gonorrhea, new strategies are needed to overcome this situation.
One plausible method might be "antibiotic cycling". (2) This is a strategy in which antibiotics from different antibiotic classes are alternated periodically over a set period of time ultimately returning to the original antibiotic. (3) This in a way prevents the development of resistance. For instance in one recent 2 year study antibiotic cycling was shown to significantly decrease the incidence of gram positive coccal infections. (4) In this study fluoroquinolones as well as cephalosporins were used in rotation with other antibiotics such as imipenems. In the context of gonorrhea, this would mean restricting the use of fluoroquinolones for a certain time period and instead using another alternative such as penicillins or cephalosporins for that duration. Antibiotic cycling has been shown to work in other situations (5) and applying it for the long term management of gonorrhea seems a reasonable strategy.
1. Wang SA, Harvey AB, Conner SM, Zaidi AA, Knapp JS, Whittington WL, et al. Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance. Ann Intern Med. 2007;147(2):81-8.
2. Masterton RG. Antibiotic cycling: more than it might seem? J Antimicrob Chemother. 2005;55(1):1-5.
3. Pujol M, Gudiol F. Evidence for antibiotic cycling in control of resistance. Curr Opin Infect Dis. 2001;14(6):711-5.
4. Raymond DP, Pelletier SJ, Crabtree TD, Gleason TG, Hamm LL, Pruett TL, et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med. 2001;29(6):1101-8.
5. Dominguez EA, Smith TL, Reed E, Sanders CC, Sanders WE,Jr. A pilot study of antibiotic cycling in a hematology-oncology unit. Infect Control Hosp Epidemiol. 2000;21(1 Suppl):S4-8.
Dear Dr. Arkfeld,
Thank you for your letter.
As noted in the Results section reviewing the demographic characteristics of GISP patients, African American men were underrepresented in GISP compared with their proportion among nationally reported male patients with gonorrhea: during 1988-2003, 74.1% of GISP patients were African American while during that same time period, 83.0% of male patients reported through the national notifiable disease reporting system to have gonorrhea in the United States were African American . Reporting of gonorrhea cases occurs as a result of healthcare provider and/or laboratory reporting of gonorrhea cases to local health departments which, in turn, report these results to the Centers for Disease Control and Prevention. In 2005, the gonorrhea rate among African Americans was 18 times greater than the rate for whites ; in years prior to 2005, the difference in gonorrhea rates between the two groups was larger (see Figure 17 ).
It is possible that persons who are symptomatically treated for gonorrhea without laboratory confirmation may be less likely to get reported to health departments but persons who undergo laboratory testing, such as nucleic acid amplification diagnostic tests, and have positive gonococcal test results are likely to get reported due to health department reporting requirements for laboratories.
Susan A. Wang, MD, MPH
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control & Prevention
1. Wang SA, Harvey AB, Conner SM, et al. Antimicrobial resistance for Neisseria gonorrheoae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance. Ann Intern Med 2007;147:81-88.
3. Centers for Disease Control and Prevention, Figure 17. Gonorrhea "” Rates by race/ethnicity: United States, 1996"“2005. http://www.cdc.gov/std/stats/figures/fig17.htm
The In the Clinic® slide sets are owned and copyrighted by the American College
of Physicians (ACP). All text, graphics, trademarks, and other intellectual property
incorporated into the slide sets remain the sole and exclusive property of the ACP.
The slide sets may be used only by the person who downloads or purchases them and
only for the purpose of presenting them during not-for-profit educational activities.
Users may incorporate the entire slide set or selected individual slides into their
own teaching presentations but may not alter the content of the slides in any way
or remove the ACP copyright notice. Users may make print copies for use as hand-outs
for the audience the user is personally addressing but may not otherwise reproduce
or distribute the slides by any means or media, including but not limited to sending
them as e-mail attachments, posting them on Internet or Intranet sites, publishing
them in meeting proceedings, or making them available for sale or distribution in
any unauthorized form, without the express written permission of the ACP. Unauthorized
use of the In the Clinic slide sets will constitute copyright infringement.
to gain full access to the content and tools.
Learn more about subscription options